Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome.
Lee, Ji-Sook, Lacerda, Eliana, Kingdon, Caroline et al. · Journal of translational medicine · 2025 · DOI
Quick Summary
This study compared immune system profiles in 96 ME/CFS patients with either mild/moderate or severe disease. Researchers found that people with severe ME/CFS had more activated immune cells and higher levels of inflammatory chemicals, while those with milder disease showed different patterns suggesting their bodies were responding to chronic viral infection. These findings suggest that mild and severe ME/CFS may involve different underlying immune problems, which could eventually help doctors predict disease severity and develop targeted treatments.
Why It Matters
This research provides objective immune markers that could help distinguish between different types of ME/CFS and predict disease severity, addressing a critical gap in clinical diagnosis and prognosis. By identifying different immune dysfunction patterns in mild versus severe disease, it opens pathways for developing stratified, targeted treatments rather than one-size-fits-all approaches. This work validates that ME/CFS has measurable biological underpinnings and is not solely psychological.
Observed Findings
Mild/moderate ME/CFS cases had increased expression of cytotoxic effector molecules and higher proportions of CD28−CD57− early-immunosenescence cells.
Severe ME/CFS cases showed significantly higher proportions of activated lymphocytes marked by CD69+ and CD38+ expression.
Severe ME/CFS patients produced elevated levels of pro-inflammatory cytokines (interferon-γ, tumor necrosis factor, interleukin-17) following in vitro stimulation.
These immunological differences were consistent across multiple cell types: CD8+ T cells, mucosal-associated invariant T cells, and natural killer cells.
The findings suggest generalized altered cytotoxic responses across both innate and adaptive immune systems stratified by disease severity.
Inferred Conclusions
Mild/moderate and severe ME/CFS represent distinct immunological phenotypes reflecting different disease pathogenesis mechanisms—one involving persistent viral immune response and the other involving sustained non-specific inflammation.
Objective immunological markers could potentially be used to stratify ME/CFS patients for prognostic purposes and targeted therapeutic development.
Altered cytotoxic immune responses are a central feature of ME/CFS pathology affecting multiple cell types across immune system compartments.
Remaining Questions
Do these immune profiles remain stable over time, or do they change as disease progresses or with treatment?
What This Study Does Not Prove
This cross-sectional study cannot prove that these immune differences cause disease severity—the relationship could be reversed or influenced by unmeasured factors. It does not establish whether these immune patterns are stable over time or change as disease progresses. The study cannot determine whether targeted immune interventions based on these markers would improve outcomes.